Search Results

Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.

Chromocell Therapeutics Corp. today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.

Perseus Therapeutics, a pioneering biopharmaceutical company based in New York City, is proud to announce the development of a novel thymic stromal lymphopoietin (TSLP) antibody aimed at preventing hair loss in cancer patients and treating a range of inflammatory diseases, including asthma.

Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead Pharmaceuticals on RNAi-based medicines.

Medivir AB announced today that its partner Vetbiolix, a veterinary biotechnology company based in France , reported positive results from a Proof-of-Concept clinical study in periodontal disease in dog with its drug candidate VBX-1000, previously known as MIV-701.

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity.

Eli Lilly is aggressively ramping up its manufacturing capacity for tirzepatide as compounding pharmacies continue to challenge an FDA decision to formally end the shortage of the obesity and diabetes drug.